Céline Jacquemont

2.2k total citations · 1 hit paper
22 papers, 1.6k citations indexed

About

Céline Jacquemont is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Céline Jacquemont has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Céline Jacquemont's work include DNA Repair Mechanisms (8 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Céline Jacquemont is often cited by papers focused on DNA Repair Mechanisms (8 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Céline Jacquemont collaborates with scholars based in United States, France and Canada. Céline Jacquemont's co-authors include Toshiyasu Taniguchi, Elizabeth M. Swisher, Jake Higgins, Emily Villegas, Fergus J. Couch, Wataru Sakai, Mukesh K. Agarwal, Nicole Urban, Beth Y. Karlan and Cynthia Friedman and has published in prestigious journals such as Nature, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Céline Jacquemont

18 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

2008 792 citations Wataru Sakai, Elizabeth M. Swisher et al. Nature profile →

Peers

Countries citing papers authored by Céline Jacquemont

Since Specialization

Citations

This map shows the geographic impact of Céline Jacquemont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Céline Jacquemont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Céline Jacquemont more than expected).

Fields of papers citing papers by Céline Jacquemont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Céline Jacquemont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Céline Jacquemont. The network helps show where Céline Jacquemont may publish in the future.

Co-authorship network of co-authors of Céline Jacquemont

This figure shows the co-authorship network connecting the top 25 collaborators of Céline Jacquemont. A scholar is included among the top collaborators of Céline Jacquemont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Céline Jacquemont. Céline Jacquemont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report 2025 ·Frontiers in Oncology ·(unknown), (unknown), Mark N. Stein, (unknown), Markus Y. Mapara, Céline Jacquemont, Ran Reshef	0
2	PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial 2024 ·Nature Communications ·Mark N. Stein, Ecaterina E. Dumbrava, Benjamin A. Teply, Usama Gergis, (unknown), Ran Reshef, Sumit K. Subudhi, Céline Jacquemont, (unknown), J. Henri Bayle, Charity D. Scripture, (unknown), Mehmet Asım Bilen, Walter M. Stadler, Carlos Becerra	18
3	209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors 2021 ·Annals of Oncology ·Samuel J. Klempner, M. Beeram, Dhanusha Sabanathan, Anthony W.H. Chan, Erika Hamilton, Sherene Loi, D-Y. Oh, Leisha A. Emens, Amita Patnaik, (unknown), Y.H. Park, Valerie Odegard, (unknown), Geundoo Jang, Céline Jacquemont, Naomi Hunder, Sarina A. Piha‐Paul	20
4	393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers 2021 ·SHILAP Revista de lepidopterología ·Samuel J. Klempner, John H. Strickler, (unknown), Céline Jacquemont, (unknown), Naomi Hunder, Valerie Odegard, Sarina A. Piha‐Paul	6
5	Abstract 5535: SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors 2020 ·Cancer Research ·Haley D. Neff‐LaFord, Juneko E. Grilley‐Olson, David C. Smith, Brendan D. Curti, Sanjay Goel, Timothy M. Kuzel, Svetomir N. Markovic, Olivier Rixe, David L. Bajor, Thomas F. Gajewski, Martin Gutierrez, Elisabeth I. Heath, John A. Thompson, Sahar Ansari, Shyra J. Gardai, Céline Jacquemont, Michael Schmitt, Andrew L. Coveler	5
6	438 Synergy between SEA-CD40 and chemotherapeutics drives curative antitumor activity in preclinical models 2020 ·SHILAP Revista de lepidopterología ·Weiping Zeng, Haley D. Neff‐LaFord, Sahar Ansari, Céline Jacquemont, Michael Schmitt, Shyra J. Gardai	0
7	617 Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death 2020 ·SHILAP Revista de lepidopterología ·Elizabeth Gray, Kelly Hensley, (unknown), Esther S. Trueblood, John J. Gosink, (unknown), Kaleb Smith, Céline Jacquemont, Mark Bieda, Jason Gow, Jeffrey R. Harris, Lauren Brady, Ibrahima Soumaoro, Shweta Jain, Leonardo Nicacio, Shyra J. Gardai	7
8	SGNBCMA-001: A phase 1 study of SEA-BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma. 2019 ·Journal of Clinical Oncology ·Al‐Ola Abdallah, James E. Hoffman, Mark A. Schroeder, Céline Jacquemont, Hong Li, Yinghui Wang, Heather Van Epps, Mary S. Campbell	9
9	DGCR8 Mediates Repair of UV-Induced DNA Damage Independently of RNA Processing 2017 ·Cell Reports ·Philamer Calses, Kiranjit K. Dhillon, (unknown), Yong Chi, Jen‐Wei Huang, Masaoki Kawasumi, Paul Nghiem, Yemin Wang, Bruce E. Clurman, Céline Jacquemont, Philip R. Gafken, Kaoru Sugasawa, Masafumi Saijo, Toshiyasu Taniguchi	28
10	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer 2016 ·Journal of Histochemistry & Cytochemistry ·Brandon S. Sheffield, Regan Fulton, Steve E. Kalloger, Katy Milne, (unknown), Martin Jones, Céline Jacquemont, (unknown), Eric Y. Stutheit-Zhao, Erin Pleasance, Janessa Laskin, Steven J.M. Jones, Marco A. Marra, Stephen Yip, Brad H. Nelson, Allen M. Gown, Cheryl Ho, Diana N. Ionescu	28
11	Biomarker Development for Cancer Immuno-oncology/Immunotherapy: Simultaneous Digital Counting of Nucleic Acids and Proteins at 800-plex 2016 ·The Journal of Immunology ·Sarah Warren, Lucas Dennis, Steven P. Fling, Patrick Danaher, Irena Pekker, Leonard D’Amico, (unknown), Melissa A. Geller, Céline Jacquemont, (unknown), (unknown), Christina E. Bailey, Kunle Odunsi, Alessandra Cesano, Joseph Beechem	0
12	FANCI Regulates Recruitment of the FA Core Complex at Sites of DNA Damage Independently of FANCD2 2015 ·PLoS Genetics ·María Castellà, Céline Jacquemont, Elizabeth L. Thompson, (unknown), (unknown), Jen‐Wei Huang, Alexandra Sobeck, Eric A. Hendrickson, Toshiyasu Taniguchi	62
13	Preliminary validation of nCounter PanCancer immune profiling of FFPE slides and pbmc in CITN-05, a CITN study of the immunological effects of an IDO1 inhibitor in patients with ovarian carcinoma 2015 ·Journal for ImmunoTherapy of Cancer ·Lucas Dennis, Steven P. Fling, Joseph Beechem, Patrick Danaher, Leonard D’Amico, Mary L. Disis, (unknown), Melissa A. Geller, Céline Jacquemont, Steven J. Kussick, (unknown), Kunle Odunsi	0
14	Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin 2012 ·Molecular Cancer ·Céline Jacquemont, Julian A. Simon, Alan D. D’Andrea, Toshiyasu Taniguchi	55
15	Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma 2009 ·Cancer Research ·Wataru Sakai, Elizabeth M. Swisher, Céline Jacquemont, (unknown), Fergus J. Couch, Simon P. Langdon, Kaitlyn Wurz, Jake Higgins, Emily Villegas, Toshiyasu Taniguchi	242
16	Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers breakdown → 2008 ·Nature ·Wataru Sakai, Elizabeth M. Swisher, Beth Y. Karlan, Mukesh K. Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas, Céline Jacquemont, Daniel J. Farrugia, Fergus J. Couch, Nicole Urban, Toshiyasu Taniguchi	792
17	Proteasome Function Is Required for DNA Damage Response and Fanconi Anemia Pathway Activation 2007 ·Cancer Research ·Céline Jacquemont, Toshiyasu Taniguchi	163
18	The Fanconi anemia pathway and ubiquitin 2007 ·BMC Biochemistry ·Céline Jacquemont, Toshiyasu Taniguchi	46
19	A new model of pre-B acute lymphoblastic leukemia chemically induced in rats 2005 ·Experimental Hematology ·(unknown), (unknown), Céline Jacquemont, Pascale Chrétien, Philippe Helissey, Jean‐Jacques Guillosson, Michel Arock, J Nafziger	3
20	A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining 2002 ·Oncogene ·Céline Baldeyron, (unknown), Julianne Smith, Céline Jacquemont, (unknown), Sophie Gad, Jean Feunteun, Dominique Stoppa‐Lyonnet, D. Papadopoulo	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact